Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Friday morning. The firm issued a hold rating on the stock.

A number of other research analysts have also recently issued reports on EKSO. Lake Street Capital assumed coverage on Ekso Bionics in a research report on Monday, June 24th. They issued a buy rating and a $2.50 target price on the stock. HC Wainwright upped their target price on Ekso Bionics from $9.25 to $10.00 and gave the company a buy rating in a report on Tuesday, April 30th.

Ekso Bionics Stock Down 1.4 %

EKSO stock opened at $1.04 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.81 and a quick ratio of 2.11. The stock has a market capitalization of $18.90 million, a price-to-earnings ratio of -1.07 and a beta of 1.51. The business’s fifty day moving average price is $1.20 and its two-hundred day moving average price is $1.60. Ekso Bionics has a fifty-two week low of $0.62 and a fifty-two week high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. The company had revenue of $3.76 million during the quarter, compared to the consensus estimate of $4.99 million. During the same quarter in the previous year, the business posted ($0.33) EPS. On average, equities analysts anticipate that Ekso Bionics will post -0.43 earnings per share for the current year.

Hedge Funds Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Strategic Wealth Investment Group LLC lifted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 21.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,950 shares of the company’s stock after purchasing an additional 9,285 shares during the quarter. Strategic Wealth Investment Group LLC owned 0.37% of Ekso Bionics worth $130,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.